Alan Pestronk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6698189/publications.pdf

Version: 2024-02-01

87 papers	6,420 citations	71102 41 h-index	69250 77 g-index
93 all docs	93 docs citations	93 times ranked	8841 citing authors

#	Article	IF	Citations
1	Cardiac and pulmonary findings in dysferlinopathy: A 3â€year, longitudinal study. Muscle and Nerve, 2022, 65, 531-540.	2.2	9
2	Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology, 2022, 13, 828525.	2.4	4
3	Randomized phase 2 study of <scp>ACE</scp>â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	2.2	8
4	Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology, 2022, 98, .	1.1	10
5	Treatable, motorâ€sensory, axonal neuropathies with C5bâ€9 complement on endoneurial microvessels. Muscle and Nerve, 2021, 63, 506-515.	2.2	2
6	Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	3.7	18
7	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Annals of Neurology, 2021, 89, 967-978.	5.3	17
8	Pathology Features of Immune and Inflammatory Myopathies, Including a Polymyositis Pattern, Relate Strongly to Serum Autoantibodies. Journal of Neuropathology and Experimental Neurology, 2021, 80, 812-820.	1.7	8
9	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
10	Cryptogenic smallâ€fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptorâ€3. Muscle and Nerve, 2020, 61, 512-515.	2.2	34
11	Chronic Graft Versus Host Myopathies: Noninflammatory, Multi-Tissue Pathology With Glycosylation Disorders. Journal of Neuropathology and Experimental Neurology, 2020, 79, 102-112.	1.7	9
12	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
13	Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Neuron, 2020, 106, 589-606.e6.	8.1	71
14	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
15	Immune myopathy with large histiocyte-related myofiber necrosis. Neurology, 2019, 92, e1763-e1772.	1.1	5
16	Prevalence of Axonal Sensory Neuropathy With IgM Binding to Trisulfated Heparin Disaccharide in Patients With Fibromyalgia. Journal of Clinical Neuromuscular Disease, 2019, 20, 103-110.	0.7	9
17	Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naÃ¯ve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscular Disorders, 2019, 29, 167-186.	0.6	59
18	Assessment of disease progression in dysferlinopathy. Neurology, 2019, 92, .	1.1	20

#	Article	IF	Citations
19	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
20	CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). Journal of Neurology, 2018, 265, 1402-1409.	3.6	40
21	Immune myopathies with perimysial pathology. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e434.	6.0	24
22	Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1224-1226.	1.9	19
23	Homozygous recessive MYH2 mutation mimicking dominant MYH2 associated myopathy. Neuromuscular Disorders, 2018, 28, 675-679.	0.6	10
24	Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1071-1081.	1.9	81
25	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	1.9	68
26	Cystinosis distal myopathy, novel clinical, pathological and genetic features. Neuromuscular Disorders, 2017, 27, 873-878.	0.6	5
27	Clinical and Laboratory Profiles of Idiopathic Small Fiber Neuropathy in Children: Case Series. Journal of Clinical Neuromuscular Disease, 2017, 19, 31-37.	0.7	12
28	Survival among children with â€œLethalâ€•congenital contracture syndrome 11 caused by novel mutations in the gliomedin gene (GLDN). Human Mutation, 2017, 38, 1477-1484.	2.5	19
29	Sarcopenia, age, atrophy, and myopathy: Mitochondrial oxidative enzyme activities. Muscle and Nerve, 2017, 56, 122-128.	2.2	9
30	Nerve ultrasound identifies abnormalities in the posterior interosseous nerve in patients with proximal radial neuropathies. Muscle and Nerve, 2016, 53, 379-383.	2.2	27
31	Myelinated and unmyelinated endoneurial axon quantitation and clinical correlation. Muscle and Nerve, 2016, 53, 198-204.	2.2	4
32	<scp>MORC</scp>2 mutations cause axonal <scp>C</scp>harcotâ€“<scp>M</scp>arieâ€“<scp>T</scp>ooth disease with pyramidal signs. Annals of Neurology, 2016, 79, 419-427.	5.3	44
33	Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology, 2016, 87, 2123-2131.	1.1	129
34	The Clinical Outcome Study for dysferlinopathy. Neurology: Genetics, 2016, 2, e89.	1.9	75
35	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
36	Myopathy with anti-HMGCR antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e124.	6.0	92

#	Article	IF	Citations
37	Dystrophinopathy mimicking metabolic myopathies. Neuromuscular Disorders, 2015, 25, 653-657.	0.6	6
38	Autophagic vacuolar pathology in desminopathies. Neuromuscular Disorders, 2015, 25, 199-206.	0.6	19
39	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
40	Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscular Disorders, 2015, 25, 289-296.	0.6	56
41	SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology, 2015, 85, 665-674.	1.1	74
42	TREM2Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 449.	9.0	221
43	Autoantibody Testing in Peripheral Neuropathy. , 2014, , 51-67.		0
44	Regional Ischemic Immune Myopathy: A Paraneoplastic Dermatomyopathy. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1126-1133.	1.7	15
45	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
46	Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle and Nerve, 2013, 48, 440-444.	2.2	65
47	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Molecular Genetics and Metabolism, 2012, 107, 456-461.	1.1	93
48	Clinical and laboratory features of neuropathies with serum IgM binding to TSâ€HDS. Muscle and Nerve, 2012, 45, 866-872.	2.2	30
49	Acquired immune and inflammatory myopathies. Current Opinion in Rheumatology, 2011, 23, 595-604.	4.3	121
50	Inflammatory Demyelinating Neuropathies. Current Treatment Options in Neurology, 2011, 13, 131-142.	1.8	9
51	Mitochondrial pathology in immune and inflammatory myopathies. Current Opinion in Rheumatology, 2010, 22, 651-657.	4.3	30
52	Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Current Opinion in Neurology, 2010, 23, 482-488.	3.6	47
53	Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle and Nerve, 2010, 42, 53-61.	2.2	53
54	Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 726-730.	1.9	27

#	Article	IF	Citations
55	A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease. New England Journal of Medicine, 2010, 362, 1396-1406.	27.0	674
56	Inflammatory myopathies with mitochondrial pathology and protein aggregates. Journal of the Neurological Sciences, 2009, 278, 25-29.	0.6	91
57	Clinical features of lateâ€onset Pompe disease: A prospective cohort study. Muscle and Nerve, 2008, 38, 1236-1245.	2.2	200
58	A phase I/IItrial of MYOâ€029 in adult subjects with muscular dystrophy. Annals of Neurology, 2008, 63, 561-571.	5.3	407
59	Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle and Nerve, 2007, 36, 107-110.	2.2	51
60	Brachio-cervical inflammatory myopathies: Clinical, immune, and myopathologic features. Arthritis and Rheumatism, 2006, 54, 1687-1696.	6.7	30
61	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone. Archives of Neurology, 2005, 62, 249.	4.5	105
62	Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle and Nerve, 2003, 27, 188-195.	2.2	39
63	Primary ?-sarcoglycan deficiency responsive to immunosuppression over three years. , 1998, 21, 1549-1553.		46
64	Inflammatory myopathy with cytochrome oxidase negative muscle fibers: Methotrexate treatment. , 1998, 21, 1724-1728.		21
65	Multifocal motor neuropathy. Neurology, 1997, 49, 1289-1292.	1.1	120
66	Childhood chronic inflammatory demyelinating neuropathies. Neurology, 1996, 47, 98-102.	1.1	104
67	Chronic motor neuropathies: Diagnosis, therapy, and pathogenesis. Annals of Neurology, 1995, 37, 43-50.	5.3	67
68	The clinical and diagnostic role of antiâ€GM₁ antibody testing. Muscle and Nerve, 1994, 17, 100-104.	2.2	95
69	Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle and Nerve, 1994, 17, 1293-1300.	2.2	23
70	Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Annals of Neurology, 1994, 35, 142-150.	5.3	95
71	The clinical correlates of high-titer IgG anti-GM1 antibodies. Annals of Neurology, 1994, 35, 234-237.	5.3	127
72	A Novel Therapy for Myasthenia Gravis by Reducing the Endocytosis of Acetylcholine Receptors. Annals of the New York Academy of Sciences, 1993, 681, 298-302.	3.8	6

#	Article	IF	Citations
73	Nerve conduction studies in amyotrophic lateral sclerosis. Muscle and Nerve, 1992, 15, 1111-1115.	2.2	97
74	Autoantibodies to GM1 ganglioside: different reactivity to GM1-liposomes in amyotrophic lateral sclerosis and lower motor neuron disorders. Journal of the Neurological Sciences, 1991, 104, 209-214.	0.6	24
75	Immunosuppressive treatment in multifocal motor neuropathy. Annals of Neurology, 1991, 30, 397-401.	5.3	206
76	Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Annals of Neurology, 1989, 25, 98-102.	5.3	97
77	The pathophysiology of penicillamine-induced myasthenia gravis. Annals of Neurology, 1986, 20, 740-744.	5.3	27
78	Polymyositis: Reduction of acetylcholine receptors in skeletal muscle. Muscle and Nerve, 1985, 8, 233-239.	2.2	12
79	Measurement of junctional acetylcholine receptors in myasthenia gravis: Clinical correlates. Muscle and Nerve, 1985, 8, 245-251.	2.2	67
80	Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Annals of Neurology, 1983, 14, 235-241.	5.3	58
81	Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle and Nerve, 1982, 5, 79-84.	2.2	25
82	Membrane myopathy: Morphological similarities to duchenne muscular dystrophy. Muscle and Nerve, 1982, 5, 209-214.	2.2	45
83	DMSO and immunity. Nature, 1981, 290, 432-432.	27.8	0
84	Critical reexamination of the thymus immunization model of myasthenia gravis. Muscle and Nerve, 1980, 3, 293-297.	2.2	6
85	Dimethyl sulphoxide reduces anti-receptor antibody titres in experimental myasthenia gravis. Nature, 1980, 288, 733-734.	27.8	31
86	Effect of muscle disuse on acetylcholine receptors. Nature, 1976, 260, 352-353.	27.8	158
87	Effect of botulinum toxin on trophic regulation of acetycholine receptors. Nature, 1976, 264, 787-789.	27.8	60